Veritas Genetics opens Asia R&D center to address genetic needs of Asian populations
Boston, USA-based Veritas Genetics, a pioneer in improving the accessibility of genetic testing, is establishing an R&D center in the Hangzhou Economic & Technological Development Area (HEDA), Hangzhou, China.
The company is also expanding its China-based leadership team. The R&D center will be dedicated to developing products that address the unique genetic needs of Asian populations.
The team is led by managing director, Jonathan Zhao, an executive with more than 15 years of Asia strategy and product launch experience with Amgen and Pfizer; Lei Li, vice president of global clinical and regulatory affairs; and Min Wang, vice president of China R&D.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze